Cases with Refractory Ascites and a Delayed Response to Tolvaptan
-
- Hagiwara Satoru
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
-
- Nishida Naoshi
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
-
- Chishina Hirokazu
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
-
- Ida Hiroshi
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
-
- Sakurai Toshiharu
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
-
- Komeda Yoriaki
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
-
- Kitano Masayuki
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
-
- Kudo Masatoshi
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
Search this article
Abstract
<p>The patient was a 67-year-old female with liver cirrhosis due to hepatitis C. She was administered furosemide at 20 mg/day and spironolactone at 25 mg/day, but the ascites did not improve. Despite the additional administration of tolvaptan at 3.75 mg/day, the response to ascites was still poor. While the dose of tolvaptan was thereafter increased to 7.5 mg/day on the 7th hospital day, the ascites still persisted. However, she continued to receive tolvaptan (7.5 mg/day) because the worsening of her subjective symptoms was mild and she wished to do so. The ascites was later found to have almost completely disappeared on computed tomography (CT) at 6 months. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 55 (22), 3273-3277, 2016
The Japanese Society of Internal Medicine